05/16/22 8:05 AMNasdaq : TCON conferenceslow floatTRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceTRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform toRHEA-AIneutral
05/11/22 4:02 PMNasdaq : TCON earningslow floatTRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateTRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform toRHEA-AIneutral
05/04/22 8:05 AMNasdaq : TCON conferencesearningslow floatTRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform toRHEA-AIneutral
04/19/22 8:05 AMNasdaq : TCON low floatTRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focusedRHEA-AIvery positive
03/23/22 8:05 AMNasdaq : TCON conferenceslow floatTRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth ConferenceTRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform toRHEA-AIneutral
03/15/22 4:02 PMNasdaq : TCON earningslow floatTRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate UpdateTRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceuticalRHEA-AIpositive
03/11/22 8:05 AMNasdaq : TCON conferenceslow floatTRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare ConferenceTRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform toRHEA-AIneutral
03/10/22 8:05 AMNasdaq : TCON fda approvallow floatTRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC ProtocolTRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics andRHEA-AIvery positive
03/04/22 8:05 AMNasdaq : TCON conferencesearningslow floatTRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform toRHEA-AIneutral
02/02/22 8:05 AMNasdaq : TCON clinical triallow floatTRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer InstituteTRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics today announced that the National Cancer Institute (NCI) has initiated a randomizedRHEA-AIneutral